الفهرس 
? Anesthetic Considerations in Patients Undergoing Bariatric SurgeryOnly 14 pages are availabe for public view
 |  | from | 155 |  |  |
| | | from | 155 | | |
Abstract
The prevalence of obesity in modern societies leads to continuous growing of bariatric surgery throughout the world as it is an effective treatment for obesity. Dexmedetomidine (DEX), a selective α2-adrenergic agonist, is an opioid-sparing adjuvant sedative that avoids respiratory depression and has been shown to be beneficial in bariatric surgery patients
Aim of the Work: The aim of this study is to evaluate the analgesic profile of intraoperative Dexmedetomidine on postoperative analgesic requirements.
Patients and Methods: This study was carried out at bariatric surgery unit - Ain shams University Hospitals and included 60 patients of both sexes undergoing elective laparoscopic bariatric surgery.
Results: The main finding in this study was that nalbuphine consumption was less in group D compared to group C with p value < 0.001 with high significant difference between the two groups also it revealed a high significant difference between the two groups according to time for first use of rescue analgesia. There was a highly significant difference between the two groups according to hemodynamics including (MAP & HR) but with no clinically significant differences. While there was no significant difference as regard SO2 or respiratory rate
Conclusion: In patients undergoing bariatric surgeries using of intraoperative dexmedetomidine infusion with its opioid-sparing effect enhanced the recovery of this study population of morbidly obese patients with minimal side-effects.